WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 14, Issue 23, 206-226. Review Article ISSN 2277–7105

IMMUNOSUPPRESSANTS THERAPY IN KIDNEY TRANSPLANTATION: A COMPRESSIVE REVIEW

Kirti Pandav*, Dr. Karishma Nikose[2], Samiksha Thaware[3], Achal Mandale[4], Siddhesh Lande[5]

[1,3,4,5]Student In J.I.P.R Kalamb

[2]Associate Professor In J.I.P.R KALAMB.

J.I.P.R Kalamb Dist. Yavatmal, Maharashtra 445001.

Article Received on 04 Nov. 2025,
Article Revised on 24 Nov. 2025,
Article Published on 01 Dec. 2025,

https://doi.org/10.5281/zenodo.17746506

***Corresponding Author**

Kirti Pandav

Student In J.I.P.R Kalamb, J.I.P.R Kalamb Dist. Yavatmal, Maharashtra 445001.

How to cite this Article: Kirti Pandav*, Dr. Karishma Nikose, Samiksha Thaware, Achal Mandale, Siddhesh Lande. (2025). Immunosuppressants Therapy In Kidney Transplantation: A Compressive Review. World Journal of Pharmaceutical Research, 14(23), 206–226.

ABSTRACT

Kidney transplantation remains the most effective treatment for patients with end-stage renal disease (ESRD), offering superior survival, enhanced quality of life, and reduced long-term healthcare costs compared to dialysis. The success of transplantation depends largely on the effectiveness of immunosuppressive therapy, which prevents graft rejection by modulating the recipient's immune response. Modern immunosuppressive regimens employ a combination of agents targeting distinct immune pathways, allowing synergistic efficacy with minimized toxicity. The principal drug classes include calcineurin inhibitors (cyclosporine, tacrolimus), antiproliferative agents (mycophenolate mofetil, azathioprine), corticosteroids, and mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus). These agents suppress T-cell activation, cytokine production, and lymphocyte proliferation—key steps in immune-mediated graft rejection.

Despite substantial advances, long-term challenges such as nephrotoxicity, infection, metabolic complications, and chronic allograft dysfunction persist. Continued research into individualized therapy, biomarker-guided dosing, and novel immunomodulatory agents promises to improve graft survival and patient outcomes. This review highlights the mechanisms, therapeutic roles, dosing strategies, and clinical considerations of the major immunosuppressive agents used in kidney transplantation.

KEYWORDS: Function of kidney, indication, type of donor, kidney transplantation procedure, complication, immunosuppressants in kidney transplantation.

1. INTRODUCTION

Kidney transplantation is the preferred treatment for patients with end-stage renal disease (ESRD), providing better survival rates, improved quality of life, and reduced longterm healthcare costs compared to dialysis. It involves the surgical placement of a healthy kidney from a living or deceased donor into a recipient whose kidneys can no longer function adequately. Since the first successful human kidney transplant in 1954 by Dr. Joseph Murray, kidney transplantation has become one of the most commonly performed solid organ transplants worldwide.[1]

The success of kidney transplantation depends on multiple factors, including donorrecipient compatibility, surgical technique, effective immunosuppressive therapy, and post-transplant monitoring. Advances in immunology and pharmacology have significantly reduced rates of acute rejection and graft loss, improving long-term outcomes.[2] However, challenges such as chronic allograft dysfunction, shortage of donor organs, and complications related to lifelong immunosuppression remain major concerns.[3]

Immunosuppressive therapy is the cornerstone of successful kidney transplantation, aimed at preventing immune-mediated rejection of the transplanted organ while minimizing drug-related toxicity and infection risk. Following transplantation, the recipient's immune system recognizes the donor kidney as foreign, activating both cellular and humoral immune responses that can lead to graft rejection. Immunosuppressive agents act at different stages of the immune response to suppress these mechanisms and promote long-term graft survival.[4]

Immunosuppressants act by inhibiting various pathways of the immune response, including T-cell activation, proliferation, and cytokine production. Modern immunosuppressive therapy typically involves a combination regimen—comprising induction therapy (administered at the time of transplantation) and maintenance therapy (long-term prevention of rejection). Commonly used drug classes include calcineurin inhibitors (tacrolimus, cyclosporine), antiproliferative agents (mycophenolate mofetil, azathioprine), corticosteroids, mTOR inhibitors (sirolimus, everolimus), and newer agents such as co-stimulation blockers (belatacept).[5]

Over the past few decades, the development of novel immunosuppressive drugs has revolutionized transplant medicine. The modern immunosuppressive regimen typically consists of a combination of drugs—including calcineurin inhibitors (such as cyclosporine and tacrolimus), antiproliferative agents (mycophenolate mofetil, azathioprine), corticosteroids, and, in some cases, mTOR inhibitors (sirolimus, everolimus). These agents work synergistically to achieve potent immunosuppression with lower toxicity than high dose monotherapy regimens.[6]

1. Calcineurin inhibitor

Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppr1essive therapy in kidney transplantation and play a crucial role in preventing allograft rejection. These agents—primarily cyclosporine (CsA) and tacrolimus (TAC)—act by inhibiting the activation of T lymphocytes, which are central to the immune response against the transplanted kidney.

The mechanism of action of CNIs involves the formation of complexes with intracellular binding proteins (cyclophilin for cyclosporine and FK-binding protein for tacrolimus). These complexes inhibit the enzyme calcineurin, which is essential for the activation of the nuclear factor of activated T cells (NFAT). NFAT promotes the transcription of interleukin-2 (IL-2) and other cytokines necessary for T-cell activation and proliferation. By blocking this pathway, CNIs effectively suppress the immune response and reduce the incidence of acute rejection episodes.[7]

The introduction of cyclosporine in the early 1980s marked a significant breakthrough in transplant medicine, dramatically improving graft and patient survival. Later, tacrolimus, a more potent and selective CNI, became the preferred agent due to its superior efficacy and lower rates of acute rejection compared to cyclosporine.[7-8]

Despite their efficacy, CNIs are associated with dose-dependent nephrotoxicity, as well as adverse effects such as hypertension, neurotoxicity, and metabolic disturbances. Therefore, careful therapeutic drug monitoring is required to maintain the balance between preventing rejection and minimizing toxicity.[9] Overall, CNIs remain an integral part of maintenance immunosuppressive regimens, often used in combination with antiproliferative agents and corticosteroids to achieve optimal outc)omes in kidney transplant recipients.[10]

2. Antiproliferat lnhibitor

Antiproliferative inhibitors play a vital role in the prevention of allograft rejection following kidney transplantation. These agents act by inhibiting the proliferation of T and B lymphocytes, thereby suppressing the immune response that could lead to graft rejection. They are typically used as part of a triple-drug immunosuppressive regimen alongside calcineurin inhibitors (CNIs) and corticosteroids. The two major antiproliferative agents used in renal transplantation are azathioprine and mycophenolate derivatives (mycophenolate mofetil [MMF] and mycophenolic acid [MPA]).

Azathioprine (AZA), a purine analog, interferes with DNA synthesis, leading to reduced proliferation of activated lymphocytes. Although effective, its use has declined due to higher rates of acute rejection and adverse effects compared to MMF.

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid, selectively inhibits inosine monophosphate dehydrogenase (IMPDH)—an enzyme essential for de novo purine synthesis in lymphocytes. This selective mechanism offers potent immunosuppression with a more favorable side-effect profile and improved graft survival outcomes compared to azathioprine.

These agents have significantly improved graft survival rates and reduced the incidence of acute rejection episodes when used in combination with CNIs such as tacrolimus or cyclosporine. However, their long-term use requires careful monitoring for side effects like gastrointestinal disturbances, leukopenia, and increased susceptibility to infections**(11)(12).**

3. mTOR inhibitor

Mammalian target of rapamycin (mTOR) inhibitors are important immunosuppressive agents used in kidney transplantation to prevent graft rejection. They act by inhibiting the mTOR pathway, which plays a critical role in cell growth, proliferation, and survival. By blocking this pathway, mTOR inhibitors such as sirolimus and everolimus suppress T-cell activation and proliferation, thereby reducing immune-mediated graft damage. These agents are often used as alternatives or adjuncts to calcineurin inhibitors to minimize nephrotoxicity and improve long-term graft survival.[4]

4. Corticosteroid

Corticosteroids are among the earliest and most widely used immunosuppressive agents in kidney transplantation. They act by suppressing inflammation and inhibiting multiple steps in

the immune response, including cytokine production and T-cell activation, thereby preventing acute and chronic graft rejection. Drugs such as prednisone and methylprednisolone are commonly used during the perioperative period and as part of long-term maintenance therapy in combination with other immunosuppressants. Although effective, corticosteroids are associated with side effects such as hypertension, hyperglycemia, and bone loss, prompting efforts to minimize or withdraw their use in some patients.[4]

2. OBJECTIVE OF KIDNEY TRANSPLANTATION

The primary objective of kidney transplantation is to **restore normal renal function** in patients with end-stage renal disease (ESRD), thereby improving survival, quality of life, and overall health outcomes compared to long-term dialysis. Transplantation aims to replace the failed kidneys with a functioning donor organ that can maintain fluid and electrolyte balance, remove metabolic waste products, and regulate endocrine functions such as erythropoietin and vitamin D metabolism. Additionally, it seeks to reduce the burden of chronic dialysis complications and enhance patient productivity and well-being.[10]

3. FUNCTION OF KIDNEY

- **Blood Filtration and Waste Removal**

The kidneys filter approximately 200 quarts of blood daily, removing waste products such as urea and creatinine, which are byproducts of protein and muscle metabolism. These wastes are excreted as urine, while essential substances like glucose, amino acids, and electrolytes are reabsorbed into the bloodstream.

- **Regulate body fluids and Electrolyte balance**

Kidneys regulate the body's fluid volume and the balance of electrolytes, including sodium, potassium, and calcium. This regulation is crucial for maintaining normal cell function and overall homeostasis.

- **Acid-Base Balance**

By excreting hydrogen ions and reabsorbing bicarbonate from urine, kidneys help maintain the blood's pH within a narrow, healthy range, typically around 7.4. This process is vital for normal cellular activities.

- **Blood Pressure Regulation**

The kidneys produce the enzyme renin, which initiates a cascade leading to the production of angiotensin II. Angiotensin II constricts blood vessels and stimulates aldosterone release, prompting sodium and water retention, thereby increasing blood pressure.

- **Erythropoiesis Regulation**

In response to low oxygen levels in the blood, kidneys release erythropoietin, a hormone that stimulates the bone marrow to produce red blood cells, ensuring adequate oxygen transport throughout the body.

- **Vitamin D Activation**

Kidneys convert vitamin D into its active form, calcitriol, which is essential for calcium absorption in the intestines and bone health.

- **Detoxification and Drug Metabolism**

Beyond filtering metabolic wastes, kidneys also eliminate various toxins and drugs, playing a significant role in detoxification processes.[13]

4. Indication for kidney transplantation

- End-Stage Renal Disease (ESRD): Characterized by a glomerular filtration rate (GFR) of less than 15 mL/min/1.73 m², indicating severe kidney dysfunction.
- Chronic Kidney Disease (CKD): Particularly stages 4 and 5, where kidney function is significantly impaired.
- Dialysis Dependency: Patients requiring chronic dialysis therapy.
- Poor Dialysis Tolerance: Individuals who experience complications or have difficulty tolerating dialysis treatments.

5. Types of Donor

Living Donor Kidney Transplantation (LDKT)

A living donor is a healthy person who donates one of their kidneys to a recipient. Living donor kidneys generally have better outcomes because the organ is transplanted quickly, reducing ischemic injury.

Subtypes of Living Donors

1. Directed Donation: The donor chooses a specific recipient (e.g., a family member or friend).
2. Non-Directed (Altruistic) Donation: The donor does not have a specific recipient; often used to start a chain of transplants.
3. Paired Kidney Exchange (Kidney Swap): Two or more incompatible donor-recipient pairs exchange kidneys to find compatible matches.
4. Expanded Criteria Living Donor: Donors above 60 years, or 50+ with certain health conditions.

Advantages

1. Shorter waiting time for transplant
2. Better graft survival
3. Immediate kidney function post-transplant
4. Lower risk of rejection

Considerations

1. Surgical risk for donor
2. Emotional and psychological impacts
3. Need for a healthy donor

Deceased Donor Kidney Transplantation (DDKT)

1. A deceased donor is someone who has died (brain death or cardiac death) and whose kidneys are donated for transplantation.
2. Subtypes of Deceased Donors:
3. Standard Criteria Donor (SCD): Usually younger individuals without significant health issues.
4. Expanded Criteria Donor (ECD): Older donors or those with certain medical conditions; kidneys may have slightly lower function than standard donor kidneys.

Advantages

1. Option for patients without living donors
2. Helps reduce organ shortage

Considerations

1. Longer cold ischemia time may affect kidney function
2. Higher risk of delayed graft function
3. Longer waiting time
4. Longer cold ischemia time may affect kidney function
5. Higher risk of delayed graft function
6. Longer waiting time

6. Compatibility test for kidney transplantation

Before a kidney transplant, several compatibility tests are performed to ensure that the donor kidney is a good match for the recipient. These tests minimize the risk of rejection and improve the success rate of the transplant.

6.1 Blood Type (ABO) Compatibility Test

1. Purpose: To check if the donor and recipient have compatible blood groups.
2. Explanation: The recipient's immune system can attack a kidney from an incompatible blood type.
3. Compatible Blood Groups:

Recipient Blood Type	Compatible Donor Types
O	
A	A, O
B	B, O
AB	A, B, AB, O (universal recipient)[14]

6.2 Human Leukocyte Antigen (HLA) Typing

1. Purpose: To identify genetic matches between donor and recipient.
2. Explanation: HLAs are proteins found on white blood cells that help the immune system recognize self vs. non-self. The more HLA matches, the lower the risk of rejection.
3. Main HLA loci tested:

- HLA-A
- HLA-B
- HLA-DR

A 6-antigen match (2 from each locus) is ideal.[15]

6.3 Crossmatch Test

1. Purpose: To detect if the recipient has preformed antibodies against the donor's antigens.

2. Types

- Complement-Dependent Cytotoxicity (CDC) Crossmatch
- Flow Cytometry Crossmatch (more sensitive)

3. Interpretation

- Negative crossmatch: No antibodies → Safe to transplant
- Positive crossmatch: Antibodies present → High risk of rejection.[16]

6.4 Panel Reactive Antibody (PRA) Test

1. Purpose: To measure the level of antibodies in the recipient's blood against a pool of HLA antigens.

2. Explanation

- High PRA (>50%) → Highly sensitized patient → More difficult to find a compatible donor.
- Low PRA (<20%) → Easier to find compatible donor.[17]

6.5 Donor-Specific Antibody (DSA) Test

1. Purpose: To detect antibodies in the recipient that are specific to the donor's HLA antigens.
2. Explanation: Presence of DSA increases risk of antibody-mediated rejection.[18]

6.6 Other Pre-Transplant Compatibility Tests

1. Tissue Crossmatch (Lymphocyte Crossmatch): Confirms no immune reaction between donor and recipient lymphocytes.
2. Serology Tests: Check for infectious diseases (HIV, Hepatitis B & C, CMV, EBV).
3. Kidney Function Tests: Evaluate donor kidney health (serum creatinine, GFR).[18]

7. KIDNEY TRANSPLANTION PROCEDURE



7.1 Preoperative Evaluation

1. Donor Evaluation
2. Donor evaluation aims to ensure safety and compatibility. It includes:
3. Blood type and HLA matching
4. Crossmatching to detect donor-specific ntibodies
5. Renal function assessment through GFR measurement and imaging
6. Screening for transmissible infections such as HIV, HBV, and HCV.[19]

Both living and deceased donors are considered. Living donors undergo extensive medical and psychological screening to confirm suitability.[20] Recipient Evaluation :Recipient assessment includes a detailed medical history, cardiovascular evaluation, and laboratory tests to determine transplant readiness. Contraindications include active infections, malignancy, or severe cardiovascular disease.[21]

7.2 Donor Nephrectomy

The donor kidney is obtained through open or laparoscopic nephrectomy. Laparoscopic approaches are now preferred for living donors due to shorter recovery time and reduced morbidity.[22] In deceased donors, kidneys are retrieved after brain or circulatory death, and perfused with cold preservation solutions such as the University of Wisconsin (UW) or histidine-tryptophan-ketoglutarate (HTK) solution to minimize ischemic injury.[23]

7.3 Recipient Surgery

Surgical Technique

The recipient operation is usually performed under general anesthesia. The donor kidney is implanted in the iliac fossa, commonly on the right side for surgical convenience.

1. Vascular Anastomosis: The renal vein is anastomosed to the external iliac vein. The renal artery is connected to the external or internal iliac artery using microsurgical suturing techniques.[24]
2. Ureteroneocystostomy: The donor ureter is implanted into the bladder using the Lich–Gregoir anti-reflux technique to prevent urinary complications.
3. Reperfusion: Once vascular anastomoses are complete, clamps are released to restore blood flow. The kidney should rapidly regain color, and urine production typically begins immediately or within hours.[25]

7.4 Postoperative Management

Effective postoperative care is essential for graft survival.

1. Immunosuppressive therapy: Typically a combination of a calcineurin inhibitor (tacrolimus or cyclosporine), an antiproliferative agent (mycophenolate mofetil or azathioprine), and corticosteroids.[25]
2. Fluid and electrolyte management: Careful monitoring of urine output and hemodynamics is critical in the early postoperative period.
3. Monitoring: Graft function is assessed by serum creatinine, urine output, and imaging.[19]

8. Complications of Kidney Transplantation

Kidney transplantation significantly improves survival and quality of life in patients with end-stage renal disease (ESRD). However, despite advances in surgical techniques and immunosuppressive therapy, several complications can occur post-transplantation, which may affect graft and patient outcomes. These complications are broadly classified as surgical, immunologic, infectious, and metabolic.

8.1 Surgical Complications

These usually occur in the early postoperative period and include:

1. Vascular complications: Thrombosis, stenosis, or leakage of the renal artery or vein may lead to graft loss.
2. Urological complications: Urine leakage, ureteral obstruction, and lymphocele formation are common.

3. Wound complications: Hematoma, infection, or dehiscence can occur, particularly in obese or diabetic patient.[4]

8.2 Immunologic Complications

1. Hyperacute rejection: Occurs within minutes to hours due to preformed antibodies against donor antigens.
2. Acute rejection: Usually within weeks to months; mediated by T-cells or antibodies and managed with immunosuppressive therapy.
3. Chronic rejection (chronic allograft nephropathy): Progressive fibrosis and vascular changes leading to gradual loss of graft function.[26]

8.3 Infectious Complications

Due to long-term immunosuppression, transplant recipients are at high risk for infections such as:

1. Bacterial: Urinary tract infections (most common).
2. Viral: Cytomegalovirus (CMV), BK virus nephropathy, Epstein–Barr virus (EBV).
3. Fungal: Candida, Aspergillus infections in severely immunosuppressed patients.[27]

8.4 Malignancy and Recurrence of Primary Disease

Post-transplant malignancies: Increased risk of skin cancer, lymphomas (especially post-transplant lymphoproliferative disorder, PTLD).

Recurrence: Some primary kidney diseases (e.g., focal segmental glomerulosclerosis, IgA nephropathy) may recur in the graft.[28]

9. Immuno-suppressants therapy in kidney transplantation

Immunosuppressive therapy is essential in kidney transplantation to prevent acute and chronic graft rejection by suppressing the recipient's immune response against donor antigens. The goal is to maintain graft function while minimizing toxicity and infection risk.

1. Calcineurin inhibitor (CNIs)
2. Antiproliferate Inhibitor
3. mTOR
4. Corticosteroid

- **Induction agents**
  - T-cell depleting antibodies (rabbit antithymocyte globulin, rATG): polyclonal antibodies causing profound lymphocyte depletion; commonly used for high-immunologic-risk recipients to lower acute rejection rates. Randomized and comparative studies show lower early rejection vs IL-2 receptor antagonists in some settings.
  - IL-2 receptor antagonists (basiliximab): non-depleting blockade of IL-2R (CD25) used for lower-risk patients; favorable safety profile but less potent than rATG for high-risk recipients. Meta-analyses and trials guide choice based on immunologic risk.[29]



9.1 Calcineurin Inhibitors (CNIs)

1. **Cyclosporine**

- Mechanism of Action: Cyclosporine binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking the dephosphorylation of nuclear factor of activated T cells (NFAT) and preventing IL-2 transcription, essential for T-cell activation.
- Dose: Initial: 5–10 mg/kg/day (oral or IV, divided doses).
- Maintenance: 2–6 mg/kg/day, adjusted based on trough levels (target 100–300 ng/mL).
- Effects: Prevents acute rejection and promotes graft survival; however, nephrotoxicity and hypertension are common adverse effects.[30]

2. Tacrolimus

- Mechanism of Action: Tacrolimus binds to FK506-binding protein (FKBP12), forming a complex that inhibits calcineurin, suppressing IL-2 transcription and T-cell activation.
- Dose: Initial: 0.1–0.2 mg/kg/day (oral, in two divided doses).
- Maintenance: 0.05–0.1 mg/kg/day, target trough 5–15 ng/mL.
- Effects: More potent than cyclosporine, with reduced acute rejection rates but increased risk of diabetes mellitus and neurotoxicity.[31-32]

9.2 Antiproliferative Agents

1. Mycophenolate Mofetil (MMF)

- Mechanism of Action: Inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo guanosine nucleotide synthesis, thus suppressing proliferation of activated T and B lymphocytes.
- Dose: 1–1.5 g twice daily (oral) or 1 g twice daily (IV).
- Effects: Reduces acute rejection when used with CNIs; adverse effects include gastrointestinal disturbances and leukopenia.[33-34]

2. Azathioprine

- Mechanism of Action: Converted to 6-mercaptopurine, which inhibits DNA synthesis and lymphocyte proliferation.
- Dose:1–2 mg/kg/day (oral).
- Effects: Older agent; now less commonly used. Associated with myelosuppression and hepatotoxicity.[35]

9.3 mTOR Inhibitors References

1. Sirolimus (Rapamycin)

- Mechanism of Action: Binds to FKBP12, forming a complex that inhibits mTOR (mammalian target of rapamycin), blocking IL-2–mediated T-cell proliferation.
- Dose: Loading: 6 mg orally, followed by 2 mg/day; adjust for target trough 5–15 ng/mL.
- Effects: Reduces chronic rejection; nephrotoxicity less severe than CNIs, but delayed wound healing and hyperlipidemia common.[36-37]

2. Everolimus

- Mechanism of Action: Similar to sirolimus—blocks mTOR, inhibiting T-cell proliferation.
- Dose: 0.75 mg twice daily, adjusted for trough 3–8 ng/mL.
- Effects: Allows CNI minimization; main adverse effects are dyslipidemia and mouth ulcers.[38]

9.4 Corticosteroids

1. Prednisolone / Methylprednisolone

- Mechanism of Action: Suppresses multiple inflammatory cytokines, decreases T-cell activation, and reduces expression of adhesion molecules.
- Dose: Induction: IV methylprednisolone 500–1000 mg intraoperatively or immediately post-transplant.
- Maintenance: Oral prednisolone 5–20 mg/day, tapered over months.[39]
- Effects: Prevents acute rejection; long-term use associated with diabetes, hypertension, osteoporosis, and Cushingoid features.[39]

10. COMBINATION THERAPY IN KIDNEY TRANSPLANTATION

Use combination (triple) immunosuppressive therapy, which acts on different immune pathways to provide synergistic immunosuppression while allowing lower doses of individual agents. This strategy reduces adverse effects and improves both graft survival and patient outcomes.

Drug given as combination

1. Tacrolimus + Mycophenolate mofetil + Prednisone
2. Cyclosporine + Mycophenolate mofetil + Prednisone
3. Tacrolimus + Azathioprine + Prednisone
4. CNI + mTOR inhibitor (Sirolimus/Everolimus) + Steroid (in CNI minimization protocols)

Clinical Benefits

1. Prevention of Acute and Chronic Rejection:

- One of the most important benefits of immunosuppressive therapy is the prevention of graft rejection.

- Acute rejection, which commonly occurs within weeks to months after transplantation, is effectively controlled by calcineurin inhibitors (e.g., tacrolimus, cyclosporine) and corticosteroids.
- Chronic rejection, which leads to gradual graft failure, is minimized through the use of combination therapy (CNI + antiproliferative + corticosteroid) and by maintaining adequate immunosuppressive levels.
- As a result, the incidence of acute rejection has decreased from >50% in the 1980s to <10% today.

2. Improved Graft Survival and Function

➢ Immunosuppressive therapy has significantly prolonged graft survival:

- One-year graft survival rates now exceed 90–95% in most transplant centers.
- Long-term survival has also improved, with many patients maintaining functioning grafts beyond 10–15 years.
- The use of more selective drugs such as tacrolimus and mycophenolate mofetil has led to better renal function and lower rejection rates compared to older regimens.

3. Enhanced Patient Survival and Quality of Life

➢ By preserving kidney function, immunosuppressive therapy allows patients to:

- Avoid long-term dialysis and its complications.
- Maintain near-normal fluid, electrolyte, and metabolic balance.
- Experience improved quality of life, physical well-being, and productivity.
- Studies have shown that kidney transplant recipients live longer and healthier lives compared to patients who remain on dialysis.

4. Reduced Need for Re-transplantation

- Effective immunosuppression minimizes immune-mediated graft loss, thereby reducing the need for repeat transplantation. This conserves scarce donor organs and decreases the physical and psychological burden on patients.

5. Development of Tailored and Safer Regimens

- Advances in pharmacology have enabled the use of individualized therapy, minimizing drug toxicity while maintaining efficacy.
- Therapeutic drug monitoring (TDM) ensures optimal dosing of calcineurin inhibitors.

- Introduction of mTOR inhibitors (sirolimus, everolimus) and costimulation blockers (belatacept) allows for calcineurin inhibitor minimization, reducing nephrotoxicity and metabolic complications.
- This leads to safer long-term outcomes and improved graft function.

6. Reduction in Alloimmune and Inflammatory Injury

- Immunosuppressants decrease T-cell activation, cytokine release, and antibody-mediated damage to the graft. This reduces:
- Inflammation and fibrosis within the transplanted kidney.
- Chronic allograft nephropathy, one of the major causes of late graft loss.

7. Facilitation of Novel Therapies and Tolerance Strategies

- Modern immunosuppressive regimens provide a platform for newer strategies aiming at immune tolerance — such as regulatory T-cell therapy, costimulatory blockade, and chimerism induction — which could one day eliminate the need for lifelong drug therapy.[40][41]42]

11. FUTURE PERSPECTIVE

The future of immunosuppressive therapy is moving toward safer, more personalized, and targeted treatments. The main aim is to protect the transplanted kidney while reducing long-term side effects like infections, cancer, and toxicity.

1. **Personalized medicine:** Doctors will adjust drug doses based on each patient's genes and body response to achieve the best effect with fewer side effects.

2. **New biologic and cell-based therapies:** New drugs like belatacept and cell therapies (such as regulatory T cells) are being developed to control the immune system more precisely and may one day allow some patients to live without lifelong immunosuppressants.

3. **Better monitoring tools:** Modern tests like donor-derived cell-free DNA and biomarkers will help detect early signs of rejection without the need for frequent kidney biopsies.

4. **Artificial intelligence and digital health:** AI may soon help doctors predict rejection risks and guide drug adjustments automatically, improving patient care.

5. Xenotransplantation and new approaches: Research on animal organ transplants (like genetically modified pig kidneys) is opening new areas that will need new, specialized immunosuppressive strategies.[43]

CONCLUSION

Immunosuppressive therapy is the cornerstone of successful kidney transplantation, enabling long-term graft function and patient survival by preventing immune-mediated rejection. Calcineurin inhibitors remain the foundation of most maintenance regimens, while antiproliferative agents, corticosteroids, and mTOR inhibitors provide complementary mechanisms to achieve optimal immunosuppression. Although these therapies have markedly reduced acute rejection rates, challenges such as chronic nephrotoxicity, metabolic adverse effects, infection, and malignancy remain significant barriers to lifelong graft success. Future advancements in transplant immunology, pharmacogenomics, and precision dosing are expected to refine immunosuppressive protocols, minimize toxicity, and promote individualized patient care. A balanced approach—combining effective immune control with minimized adverse effects—continues to be the ultimate goal in kidney transplant immunosuppression.

REFERENCE

1. Matas, A. J., Smith, J. M., Skeans, M. A., et al. OPTN/SRTR 2020 Annual Data Report: Kidney. American Journal of Transplantation, 2022; 22(Suppl 2): 21–136. https://doi.org/10.1111/ajt.16851
2. Hariharan, S., Israni, A. K., & Danovitch, G. M. Long-term survival after kidney transplantation. New England Journal of Medicine, 2021; 385(8): 729–743. https://doi.org/10.1056/NEJMra2014530
3. Meier-Kriesche, H. U., & Kaplan, B. Death after graft loss: A neglected outcome in renal transplantation. American Journal of Transplantation, 2020; 20(1): 1–9. https://doi.org/10.1111/ajt.15565
4. Halloran, P. F. Immunosuppressive drugs for kidney transplantation. New England Journal of Medicine, 2004; 351(26): 2715–2729. https://doi.org/10.1056/NEJMra033540
5. Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., et al. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Kidney International Supplements, 2020; 10(1): e1–e155.

6. Liu, C., Chen, L., & Xu, X. Current progress in immunosuppressive therapy after kidney transplantation. Frontiers in Pharmacology, 2018; 9: 1–12. https://doi.org/10.3389/fphar.2018.01236
7. Shapiro R. Tacrolimus (FK506): An overview. Transplantation Proceedings, 1999; 31(7A Suppl): 21S–24S.
8. Ekberg H, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New England Journal of Medicine, 2007; 357(25): 2562–2575.
9. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clinical Journal of the American Society of Nephrology, 2009; 4(2): 481–508.
10. KDIGO clinical practice guidelines for the care of kidney transplant recipients .Am J transplant, 2009; 9(supp 3): S1-S1 55.
11. Allison AC, Eugui EM. "Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection." Transplantation, 2005; 80(2 Suppl): S181–S190.
12. Webster AC, Taylor RR, Chapman JR, Craig JC. "Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients." Cochrane Database of Systematic Reviews, 2005; (4): CD003961.
13. Murray JE.Marrill JP. Harrison JH. Homotransplantation identical twins.surg forum, 1955; 6: 432-436.
14. Levey AS, et al. Kidney transplantation: Principles and practice. N Engl J Med., 2003; 349(8): 747–759.
15. Hertzog P, et al. The role of HLA matching in kidney transplantation. Transplant Rev (Orlando). 2020; 34(4): 100562.
16. Cecka JM. The crossmatch in kidney transplantation. Clin Transpl., 2008; 397–404.
17. Tambur AR, et al. Sensitization in transplantation: Assessment and management. Transplantation, 2018; 102(1S Suppl 1): S21–S30.
18. Tait BD, et al. Detection of donor-specific antibodies in kidney transplantation. Transplant Rev (Orlando)., 2016; 30(3): 125–131.
19. Siedlecki, A., Irish, W., Brennan, D. C. Delayed graft function in the kidney transplant. American Journal of Transplantation, 2011; 11(11): 2279–2296.
20. Abecassis, M. M., Bartlett, S. T., Collins, A. J., et al. Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/KDOQI conference. Clinical Journal of the American Society of Nephrology, 2008; 3(2): 471–480.

21. Kasiske, B. L., Zeier, M. G., Craig, J. C., et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation, 2010; 10(S1): S1–S155.
22. Gillen, D. L., Stehman-Breen, C., et al. Living donor nephrectomy: Outcomes and surgical considerations. American Journal of Kidney Diseases, 2018; 72(3): 350–359.
23. Nankivell, B. J., & Alexander, S. I. Rejection of the kidney allograft. New England Journal of Medicine, 2010; 363(15): 1451–1462.
24. Benedetti, E., Asolati, M., Dunn, T. B., et al. Surgical aspects of kidney transplantation: State of the art. Transplantation Reviews, 2010; 24(2): 77–83.
25. Webster, A. C., Woodroffe, R. C., Taylor, R. S., Chapman, J. R., Craig, J. C. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis. BMJ, 2008; 331(7520): 810.
26. Ponticelli C, Cucchiari D, Graziani G. Current and future immunosuppressive strategies in kidney transplantation. Pharmacol Res., 2020; 146: 104–284. Doi: 10.1016/j.phrs.2019.10428
27. Fishman JA. Infection in organ transplantation. Am J Transplant., 2017; 17(4): 856–879. Doi: 10.1111/ajt.14208
28. Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: A UK Registry audit. Am J Transplant., 2010; 10(8): 1889–1896. Doi:10.1111/j.1600-6143.2010.03206.x
29. Ciancio G, Burke GW. Transplantation Reviews, 2008; 22(3): 207–214.
30. Naesens M et al. Nat Rev Nephrol., 2009; 5(11): 564–575.
31. Staatz CE, Tett SE. Clin Pharmacokinet., 2004; 43(10): 623–653.
32. Webster AC et al. Cochrane Database Syst Rev., 2005; (4): CD003961.
33. Sollinger HW. Transplantation., 1995; 60(3): 225–232.
34. Knight SR et al. Transplantation, 2009; 87(5): 785–79.
35. Hartmann A et al. Nephrol Dial Transplant., 2003; 18(Suppl 6): vi2–vi8.
36. McMahon G et al. Curr Opin Biotechnol., 2000; 11(6): 595–602.
37. Kasiske BL et al. Am J Transplant., 2010; 10(1): 1–34.
38. Campistol JM et al. Transplant Rev., 2009; 23(2): 80–89.
39. Hricik DE et al. Clin J Am Soc Nephrol., 2008; 3(Suppl 2): S103–S111.
40. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol., 2009; 4(2): 481–508.

41. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant., 2011; 11(3): 450–462.
42. Ekberg H et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med., 2007; 357(25): 2562–2575.
43. Vincenti F, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med., 2016; 374(4): 333–343.